Tag archive for ‘Type 1 diabetes’
Jewish Business News On Tuesday, December 15th, 2015

Israeli biomed’s novel technology could cure diabetes

  In people with type 1 diabetes, the insulin-producing beta cells of the pancreas don’t function properly. Daily injections or infusions of insulin are necessary to regulate energy-producing glucose More...

Globes On Tuesday, October 7th, 2014

Clal Biotech, Hyperion seek settlement over Andromeda

– Clal Biotechnology and Hyperion have agreed on an independent assessment of Andromeda’s Type 1 diabetes treatment. –   Clal Biotechnology (TASE: CBI), managed by Reuven Krupik, and More...

Jewish Business News On Thursday, June 26th, 2014

Positive Preliminary Pre-Clinical Data for RedHill Biopharma for the Treatment of Type 1 Diabetes

RedHill Biopharma Ltd.(NASDAQ: RDHL; TASE: RDHL) , today announced preliminary positive data from a pre-clinical study with RHB-104 for the treatment of type 1 diabetes, a chronic autoimmune disease with More...

Niddle , Health, Treatment
Jewish Business News On Tuesday, April 29th, 2014

Israeli Researcher May Have a Cure for Type 1 Diabetes

– Type 1 diabetes currently plagues 25.8 million Americans of all ages, about 8.3 percent of the U.S. population, according to the National Diabetes Information Clearinghouse. All type 1 diabetics More...

Jewish Business News On Thursday, April 24th, 2014

Hyperion Therapeutics acquires Israeli Andromeda Biotech for up to $570 million

– Hyperion Therapeutics (Nasdaq:HPTX) announced today that it acquires Andromeda Biotech Ltd., an Israel-based subsidiary of Clal Biotechnology Industries Ltd. (TASE:CBI), for $20 million in cash More...

Niddle , Health, Treatment
Jewish Business News Service On Monday, February 24th, 2014

First Clinical Trial of Type 1 Diabetes Treatment Has Extremely Positive Results

– The promising treatment for Type 1 diabetes developed by Dr. Eli Lewis, a BGU researcher, in collaboration with the University of Colorado Health Science Center. – A clinical study on a promising More...

Gali Weinreb On Thursday, February 20th, 2014

Teva Sells Andromeda Diabetes Treatment Stake For $72 Million

– Teva will receive $72 million from future sales or from the proceeds of an exit, if any. Diapep277 Slowing the Progression of Type 1 Diabetes. – Clal Biotechnology Industries Ltd. (TASE: CBI) More...

Jewish Business News Service On Thursday, October 31st, 2013

Kamada : New Data from an Extension Study Trial with Glassia in Pediatric Patients with Type 1 Diabetes

– Kamada plans to initiate a Phase II/III trial with Glassia with newly diagnosed type one diabetes pediatric and young adult patients. – – Kamada Ltd. (Nasdaq: KMDA); TASE: KMDA) has More...

Wordpress site Developed by Fixing WordPress Problems